Blueprint Medicines (BPMC) Competitors $129.30 -0.03 (-0.02%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$129.30 0.00 (0.00%) As of 07/11/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPMC vs. BNTX, ONC, TEVA, INSM, SMMT, ITCI, GMAB, RDY, MRNA, and RGCShould you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry. Blueprint Medicines vs. Its Competitors BioNTech BeOne Medicines Teva Pharmaceutical Industries Insmed Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience BioNTech (NASDAQ:BNTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Is BNTX or BPMC more profitable? BioNTech has a net margin of -27.37% compared to Blueprint Medicines' net margin of -27.70%. BioNTech's return on equity of -3.94% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-27.37% -3.94% -3.41% Blueprint Medicines -27.70%-64.60%-17.22% Do analysts recommend BNTX or BPMC? BioNTech currently has a consensus price target of $137.91, suggesting a potential upside of 22.17%. Blueprint Medicines has a consensus price target of $128.25, suggesting a potential downside of 0.81%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.24 Does the media prefer BNTX or BPMC? In the previous week, BioNTech had 2 more articles in the media than Blueprint Medicines. MarketBeat recorded 11 mentions for BioNTech and 9 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.23 beat BioNTech's score of 0.89 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, BNTX or BPMC? Blueprint Medicines has lower revenue, but higher earnings than BioNTech. Blueprint Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B9.11-$719.92M-$3.40-33.20Blueprint Medicines$508.82M16.41-$67.09M-$2.47-52.35 Do institutionals & insiders have more ownership in BNTX or BPMC? 15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, BNTX or BPMC? BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. SummaryBioNTech beats Blueprint Medicines on 12 of the 16 factors compared between the two stocks. Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPMC vs. The Competition Export to ExcelMetricBlueprint MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.35B$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-52.3520.5827.9620.25Price / Sales16.41292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book27.517.638.045.49Net Income-$67.09M-$55.05M$3.18B$250.27M7 Day Performance0.80%8.39%3.63%4.75%1 Month Performance0.85%5.35%4.04%7.64%1 Year Performance9.78%1.95%29.55%16.34% Blueprint Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPMCBlueprint Medicines1.0898 of 5 stars$129.300.0%$128.25-0.8%+9.8%$8.35B$508.82M-52.35640Positive NewsInsider TradeHigh Trading VolumeBNTXBioNTech1.4923 of 5 stars$110.05+0.0%$137.86+25.3%+33.3%$26.45B$2.98B-32.376,772News CoverageAnalyst ForecastONCBeOne Medicines3.446 of 5 stars$240.99-1.8%$320.67+33.1%N/A$26.41B$4.18B-64.7811,000Trending NewsAnalyst DowngradeInsider TradeTEVATeva Pharmaceutical Industries4.1288 of 5 stars$16.84-1.0%$24.13+43.3%-4.2%$19.31B$16.54B-14.6436,830Positive NewsINSMInsmed4.3574 of 5 stars$96.95-0.9%$106.80+10.2%+27.5%$18.39B$363.71M-16.291,271Analyst ForecastInsider TradeSMMTSummit Therapeutics2.8189 of 5 stars$22.61-7.9%$34.67+53.3%+188.0%$16.79B$700K-66.50110ITCIIntra-Cellular Therapies0.6601 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.101 of 5 stars$20.52+1.1%$37.60+83.2%-18.4%$13.16B$3.12B11.662,682Analyst ForecastRDYDr. Reddy's Laboratories2.7589 of 5 stars$15.08flat$16.95+12.4%-7.9%$12.59B$3.81B22.8527,811MRNAModerna4.3068 of 5 stars$29.90-1.9%$46.61+55.9%-72.6%$11.56B$3.24B-3.425,800Trending NewsRGCRegencell Bioscience0.3677 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap Down Related Companies and Tools Related Companies BNTX Competitors ONC Competitors TEVA Competitors INSM Competitors SMMT Competitors ITCI Competitors GMAB Competitors RDY Competitors MRNA Competitors RGC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPMC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.